Searchable abstracts of presentations at key conferences in endocrinology

ea0050oc1.1 | Early Career Oral Communications | SFEBES2017

Neurokinin 3 receptor antagonism is a highly effective, novel treatment for menopausal hot flushes with rapid onset: a phase 2, randomised, double-blind, placebo-controlled trial

Prague Julia , Roberts Rachel , Comninos Alexander , Clarke Sophie , Jayasena Channa , Nash Zachary , Doyle Chedie , Papadopoulou Deborah , Bloom Stephen , Mohideen Pharis , Lin Vivian , Stern Theresa , Panay Nicholas , Hunter Myra , Veldhuis Johannes , Webber Lorraine , Huson Les , Dhillo Waljit

Background: Hot flushes (HF) affect 70% of menopausal women and can be debilitating. Oestrogen administration is effective but not without risk. Neurokinin B signalling is increased in menopausal women, and is likely critical in the aetiology of their HF. We therefore hypothesised that a neurokinin 3 receptor (NK3R) antagonist could attenuate menopausal flushing.Design: This single-centre, phase 2, randomised, double-blind, placebo-controlled, crossover ...

ea0050oc1.1 | Early Career Oral Communications | SFEBES2017

Neurokinin 3 receptor antagonism is a highly effective, novel treatment for menopausal hot flushes with rapid onset: a phase 2, randomised, double-blind, placebo-controlled trial

Prague Julia , Roberts Rachel , Comninos Alexander , Clarke Sophie , Jayasena Channa , Nash Zachary , Doyle Chedie , Papadopoulou Deborah , Bloom Stephen , Mohideen Pharis , Lin Vivian , Stern Theresa , Panay Nicholas , Hunter Myra , Veldhuis Johannes , Webber Lorraine , Huson Les , Dhillo Waljit

Background: Hot flushes (HF) affect 70% of menopausal women and can be debilitating. Oestrogen administration is effective but not without risk. Neurokinin B signalling is increased in menopausal women, and is likely critical in the aetiology of their HF. We therefore hypothesised that a neurokinin 3 receptor (NK3R) antagonist could attenuate menopausal flushing.Design: This single-centre, phase 2, randomised, double-blind, placebo-controlled, crossover ...